Table 2.
Distribution of individual antibiotic groups usage in MRSA (18 cases) and MSSA (28 cases) infections
| Antibiotic groups | DOT [%] | OR (95%CI) P-value | DDD [%] | OR (95%CI) P-value | ||
|---|---|---|---|---|---|---|
| MRSA | MSSA | MRSA | MSSA | |||
| Aminoglycosides | 17.2 | 14.9 | 0.976 (0.697–1.367) 0.967 | 31.7 | 28.0 | 1.366 (1.096–1.704) 0.561 |
| Beta-lactams | 6.3 | 31.7 | 0.146 (0.092–0.233) 0.005 | 19.0 | 40.9 | 0.338 (0.264–0.435) 0.879 |
| Fluoroquinolones | 6.0 | 0.0 | n/a | 9.3 | 0.0 | n/a |
| Glycopeptides | 63.6 | 43.0 | 2.296 (1.766–2.985) 0.427 | 33.4 | 24.9 | 1.513 (1.208–1.895) 0.533 |
| Lincozamides | 2.7 | 1.1 | 2.562 (1.008–6.512) 0.221 | 0.8 | 1.0 | 0.775 (0.250–2.408) 0.073 |
| Macrolides | 4.2 | 5.8 | 0.723 (0.393–1.330) 0.832 | 2.8 | 4.4 | 0.629 (0.348–1.138) 0.072 |
| Trimethoprim/sulfamethoxazole | 0.0 | 3.0 | n/a | 0.0 | 0.2 | n/a |
| Metronidazole | 0.0 | 0.5 | n/a | 0.0 | 0.6 | n/a |
| Total | 100.0 | 100.0 | 100.0 | 100.0 | ||
OR, odds ratio; 95%CI, 95% Confidence Interval; DOT, the aggregate sum of the number of days during which at least 1 dose of antibiotic was received for each one received, days of treatment; DDD, defined daily dose expressed in days; n/a not applicable.